15/07/2014
Change of Director's Interest Notice
 
15/07/2014
Appendix 3B - New Issue Announcement, application for quotation of additional securities and agreement
 
30/06/2014
ASX Announcement - Strategic Review Outcome
 
16/06/2014
ASX Announcement - Health Canada approval of HPV testing as primary cervical cancer screening tool
 
19/05/2014
Final Placement of Unlisted Convertible Notes & Ordinary Share Placement
 
30/04/2014
Quarterly Cash Flow & Business Update
 
 

Welcome to Genera Biosystems

Genera Biosystems Limited is an Australian publicly listed company (ASX: GBI) that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSandTM bead-based technology. Genera's products compete in the global market for molecular diagnostic tests - currently valued at around US$2.6 billion, and expected to double in the next five years - and are used by commercial pathology providers. AmpaSand beads are an ideal platform for the kind of medium density multiplexed tests (5-150 analytes) of most use to pathology labs. Moreover, AmpaSand bead-based tests are high throughput, simple to use, and leverage existing laboratory infrastructure and expertise.

dnaclr.jpgcervclr.jpgpapclr.jpgcellsclr.jpglabclr.jpg

Genera's first product on sale is PapTypeTM, a highly competitive molecular diagnostic test for the simultaneous detection and genotyping of the 14 types human papillomavirus (HPV). The company has a number of other products in its development pipeline.

Genera manufactures its products at a custom-built facility in Melbourne, Australia.

Genera is also advanced in the development of a next-generation, ultra-sensitive, real-time detection system, which will have utility in a wide range of medical and non-medical applications.